Literature DB >> 14605670

Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met.

Tuan Huy Nguyen1, Nathalie Loux, Ibrahim Dagher, Corinne Vons, Ken Carey, Pascale Briand, Michelle Hadchouel, Dominique Franco, Jacqueline Jouanneau, Ralph Schwall, Anne Weber.   

Abstract

Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a retroviral amphotropic envelope displaying single-chain variable-fragment (scFv) directed against the c-Met receptor, to target the entry of recombinant retroviruses to human hepatocarcinoma cells. Four single-chain antibody fragments directed against the c-Met receptor were generated and inserted into the viral envelope protein as an N-terminal fusion. The modified envelopes were incorporated into virus particles and one of the chimeric viruses, 3D6-Env, transduced preferentially human hepatoma cells rather than proliferating human hepatocytes. In another construct, the urokinase cleavage site was inserted between the scFv moiety and the envelope. Chimeric scFv-urokinase-Env viruses transduced hepatoma cells with a similar efficiency to that of the control virus and their infectivity in human hepatocytes remained low. These results indicate that amphotropic retroviruses with engineered envelopes to display scFv directed against the c-Met receptor can efficiently and selectively deliver genes into hepatoma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605670     DOI: 10.1038/sj.cgt.7700640

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  8 in total

1.  Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.

Authors:  Yongjun Jiao; Ping Zhao; Jin Zhu; Tessa Grabinski; Zhengqing Feng; Xiaohong Guan; R Scot Skinner; Milton D Gross; Rick V Hay; Hiroshi Tachibana; Brian Cao
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

2.  In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs.

Authors:  Neelesh Sharma; Alex A Adjei
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 3.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 4.  Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma.

Authors:  Yinli Yang; Bingqing Zheng; Qiuju Han; Cai Zhang; Zhigang Tian; Jian Zhang
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

5.  A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.

Authors:  Zu-Jun Sun; Yi Wu; Wei-Hua Hou; Yu-Xiong Wang; Qing-Yun Yuan; Hui-Jie Wang; Min Yu
Journal:  Oncotarget       Date:  2017-04-25

6.  Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.

Authors:  P C Ma; M S Tretiakova; V Nallasura; R Jagadeeswaran; A N Husain; R Salgia
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

Review 7.  An update in the use of antibodies to treat glioblastoma multiforme.

Authors:  Norma Y Hernández-Pedro; Edgar Rangel-López; Gustavo Vargas Félix; Benjamín Pineda; Julio Sotelo
Journal:  Autoimmune Dis       Date:  2013-11-05

Review 8.  The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Genes (Basel)       Date:  2020-08-10       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.